How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

224 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

C S.A. Study Details Study Description Go to Brief Summary: The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy. Condition or disease Intervention/treatment Phase Epilepsy Drug: BIA 2-093 (Eslicarbazepine acetate) Phase 2 Detailed Description: This clinical study was planned to be performed as an open-label, single-centre, multiple-dose study, in 30 paediatric epileptic patients distributed by 3 age groups of 10 (...) patients each: 2-6 years [Group 1], 7-11 years [Group 2], and 12-17 years [Group 3]. The study was constituted by a 4-week baseline phase, followed by 3 consecutive 4-week treatment periods with Eslicarbazepine acetate in which patients received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day (weeks 1-4), 15 mg/kg/day (weeks 5-8) and 30 mg/kg/day or 1800 mg/day, whichever less (weeks 9-12). At the end of each 4-week treatment period, patients were hospitalised

2014 Clinical Trials

162. A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

daily) BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets. Drug: Placebo Other Name: PLC, Placebo Drug: BIA 2-093 Other Name: ESL, Eslicarbazepine acetate Experimental: Group 2 - 400 mg b.i.d. BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets. Drug: Placebo Other Name: PLC, Placebo Drug: BIA 2-093 Other Name: ESL, Eslicarbazepine acetate Experimental: Group 3- 800 mg o.d. (once daily) BIA 2-093 200mg with 200 ml potable (...) water. Identical placebo administered as oral tablets. Drug: Placebo Other Name: PLC, Placebo Drug: BIA 2-093 Other Name: ESL, Eslicarbazepine acetate Experimental: Group 4 - either 800 mg b.i.d or 1200 mg o.d. BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets. Drug: Placebo Other Name: PLC, Placebo Drug: BIA 2-093 Other Name: ESL, Eslicarbazepine acetate Outcome Measures Go to Primary Outcome Measures : Total Number of Adverse Events [ Time Frame: up to 20

2014 Clinical Trials

163. A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

to Healthy Male Adult Volunteers. Study Start Date : July 2000 Actual Primary Completion Date : October 2000 Actual Study Completion Date : October 2000 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Group 1 (20 mg) Drug: BIA 2-093 BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg Other Name: ESL, Eslicarbazepine acetate Drug: Placebo Identical placebo (...) administered as oral tablets with 200 ml potable water. Other Name: PLC Experimental: Group 2 (50 mg) Drug: BIA 2-093 BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg Other Name: ESL, Eslicarbazepine acetate Drug: Placebo Identical placebo administered as oral tablets with 200 ml potable water. Other Name: PLC Experimental: Group 3 (100 mg) Drug: BIA 2-093 BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg Other Name: ESL, Eslicarbazepine acetate Drug: Placebo

2014 Clinical Trials

164. The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period Drug: BIA 2-093 Other Name: ESL, Eslicarbazepine acetate Outcome Measures Go to Primary Outcome Measures : Maximum Observed Plasma Concentration (Cmax) [ Time Frame: pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 hours post-dose ] Maximum observed plasma concentration of BIA 2-093 Secondary Outcome Measures : Time of Occurrence (...) : Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Bial - Portela C S.A.: BIA 2-093 Eslicarbazepine acetate Additional relevant MeSH terms: Layout table for MeSH terms Eslicarbazepine acetate Anticonvulsants Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action

2014 Clinical Trials

165. An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Subjects with moderate hepatic impairment This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls Drug: BIA 2-093 Other Name: Eslicarbazepine Acetate subjects - healthy controls This was an open-label, multiple-dose, single-centre study in 2 groups of subjects (...) : subjects with moderate hepatic impairment and healthy controls Drug: BIA 2-093 Other Name: Eslicarbazepine Acetate Outcome Measures Go to Primary Outcome Measures : Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast). [ Time Frame: pre-dose and 1, 2, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 7, 9, 12 and 24 hours post-dose. ] Day 1 - Area under the plasma concentration versus time curve, AUC(0-tlast). BIA 2-194, 2-195 Glucoronide, Oxcarbazepine, BIA 2-093 Glucoronide, 2-194

2014 Clinical Trials

166. Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.

Eslicarbazepine acetate Reproductive Control Agents Physiological Effects of Drugs Contraceptive Agents, Female Anticonvulsants Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action

2014 Clinical Trials

167. An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

terms Eslicarbazepine acetate Anticonvulsants Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action

2014 Clinical Trials

168. Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

50 mg/mL Other Name: ESL, Eslicarbazepine acetate Drug: BIA 2-093 200 mg tablet Other Name: ESL, Eslicarbazepine acetate Drug: BIA 2-093 800 mg tablet Other Name: ESL, Eslicarbazepine acetate Experimental: Group B st period - One 800 mg tablet nd period - 16 mL oral suspension 50 mg/mL rd period - Four 200 mg tablets Drug: BIA 2-093 oral suspension 50 mg/mL Other Name: ESL, Eslicarbazepine acetate Drug: BIA 2-093 200 mg tablet Other Name: ESL, Eslicarbazepine acetate Drug: BIA 2-093 800 mg tablet (...) Other Name: ESL, Eslicarbazepine acetate Experimental: Group C st period - Four 200 mg tablets nd period - One 800 mg tablet rd period - 16 mL oral suspension 50 mg/mL Drug: BIA 2-093 oral suspension 50 mg/mL Other Name: ESL, Eslicarbazepine acetate Drug: BIA 2-093 200 mg tablet Other Name: ESL, Eslicarbazepine acetate Drug: BIA 2-093 800 mg tablet Other Name: ESL, Eslicarbazepine acetate Outcome Measures Go to Primary Outcome Measures : Cmax - the Maximum Plasma Concentration [ Time Frame: Blood

2014 Clinical Trials

169. Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate. Participates must be off of any EIAED for a least two weeks prior to starting the study drug Patient is taking a drug known to be a strong inhibitor or inducers of the isoenzyme CYP3A. Participants must be off a strong CYP3A inhibitors and inducers for at least two weeks prior to starting the study drug. Patient is taking a drug with known risk to promote QT prolongation and Torsade de Pointes Patient is currently using

2014 Clinical Trials

170. Oxcarbazepine and its active metabolite, (S)-licarbazepine, exacerbate seizures in a mouse model of genetic generalized epilepsy. (Abstract)

Oxcarbazepine and its active metabolite, (S)-licarbazepine, exacerbate seizures in a mouse model of genetic generalized epilepsy. Oxcarbazepine (OXC), widely used to treat focal epilepsy, is reported to exacerbate seizures in patients with generalized epilepsy. OXC is metabolized to monohydroxy derivatives in two enantiomeric forms: (R)-licarbazepine and (S)-licarbazepine. Eslicarbazepine acetate is a recently approved antiepileptic drug that is rapidly metabolized to (S)-licarbazepine (...) . It is not known whether (S)-licarbazepine exacerbates seizures. Here, we test whether OXC or either of its enantiomers exacerbates the number of spike-and-wave discharges (SWDs) in mice harboring the human γ-aminobutyric acid A receptor (GABAA)γ2(R43Q) mutation. OXC (20 mg/kg), (S)-licarbazepine (20 mg/kg), and (R)-licarbazepine (20 mg/kg) all significantly increased the number of SWDs, while their duration was unaffected. The potential for (S)-licarbazepine to exacerbate SWDs suggests that eslicarbazepine

2014 Epilepsia

171. Partial Epilepsies (Diagnosis)

E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res . 2013 Feb. 103(2-3):262-9. . Halász P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures

2014 eMedicine.com

172. Frontal Lobe Epilepsy (Treatment)

-seizure medications include gabapentin, lamotrigine, topiramate, levetiracetam, zonisamide, oxcarbazepine, pregabalin, lacosamide, clobazam, eslicarbazepine, and brivaracetam. Approximately 30% of patients with frontal lobe epilepsy will be refractory to multiple medications, and they may require evaluation for resective surgery. Other options include dietary therapy (ketogenic diet or modified Atkins diet), vagal nerve stimulation, or responsive neurostimulation. Go to for complete information

2014 eMedicine.com

173. Antiepileptic Drugs: An overview

, gastrointestinal (GI) disturbances, and alopecia are the most commonly reported adverse effects. The allergic rash is similar to the one caused by CBZ. Dose-related adverse effects include fatigue, headache, dizziness, and ataxia. Hyponatremia is mild and can be corrected by fluid restriction. Hyponatremia is uncommon in children younger than 17 years, but it occurs in 2.5% of adults and 7.4% of the elderly. Idiosyncratic reactions appear to be less common than with CBZ. Eslicarbazepine (Aptiom) is a prodrug (...) that is activated to eslicarbazepine (S-licarbazepine), the major active metabolite of oxcarbazepine. It is indicated as either adjunctive treatment or monotherapy for partial-onset seizures in adults and children 4 years and older. The initial adult dose is 400 mg PO once daily for 1 week, then increased to 800 mg PO once daily (the recommended maintenance dose). Some patients may benefit from 1,200 mg/day (maximum dose). An increase to 1,200 mg/day should only be initiated after patients tolerate 800 mg/day

2014 eMedicine.com

174. Partial Epilepsies (Treatment)

, brivaracetam, oxcarbazepine, eslicarbazepine, and vigabatrin. Most of these newer AEDs are approved as adjuncts for partial epilepsy. Note that most epilepsy specialists believe that all AEDs that have been approved by the FDA for adjunctive therapy may be effective as monotherapy, and their prescribing practices reflect this. After they are on the market, many AEDs (eg, carbamazepine, valproic acid, levetiracetam, lamotrigine) are made available in a long-acting or extended-release preparation that may (...) perampanel for refractory partial-onset seizures. Neurology . 2012 May 1. 78(18):1408-15. . Hufnagel A, Ben-Menachem E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res . 2013 Feb. 103(2-3):262-9. . Halász P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, et al. Long-term efficacy and safety

2014 eMedicine.com

175. Partial Epilepsies (Overview)

A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res . 2013 Feb. 103(2-3):262-9. . Halász P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia

2014 eMedicine.com

176. Seizures and Epilepsy: Overview and Classification (Treatment)

anticonvulsants (eg, lamotrigine, topiramate, valproic acid, zonisamide) have multiple mechanisms of action, and some (eg, phenytoin, carbamazepine, ethosuximide) have only 1 known mechanism of action. Anticonvulsants can be divided into large groups based on their mechanisms, as follows: Blockers of repetitive activation of the sodium channel: Phenytoin, carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, topiramate Enhancers of slow inactivation of the sodium channel: Lacosamide, rufinamide Gamma

2014 eMedicine.com

177. Antiepileptic Drugs: An overview

, gastrointestinal (GI) disturbances, and alopecia are the most commonly reported adverse effects. The allergic rash is similar to the one caused by CBZ. Dose-related adverse effects include fatigue, headache, dizziness, and ataxia. Hyponatremia is mild and can be corrected by fluid restriction. Hyponatremia is uncommon in children younger than 17 years, but it occurs in 2.5% of adults and 7.4% of the elderly. Idiosyncratic reactions appear to be less common than with CBZ. Eslicarbazepine (Aptiom) is a prodrug (...) that is activated to eslicarbazepine (S-licarbazepine), the major active metabolite of oxcarbazepine. It is indicated as either adjunctive treatment or monotherapy for partial-onset seizures in adults and children 4 years and older. The initial adult dose is 400 mg PO once daily for 1 week, then increased to 800 mg PO once daily (the recommended maintenance dose). Some patients may benefit from 1,200 mg/day (maximum dose). An increase to 1,200 mg/day should only be initiated after patients tolerate 800 mg/day

2014 eMedicine.com

178. Partial Epilepsies (Follow-up)

, brivaracetam, oxcarbazepine, eslicarbazepine, and vigabatrin. Most of these newer AEDs are approved as adjuncts for partial epilepsy. Note that most epilepsy specialists believe that all AEDs that have been approved by the FDA for adjunctive therapy may be effective as monotherapy, and their prescribing practices reflect this. After they are on the market, many AEDs (eg, carbamazepine, valproic acid, levetiracetam, lamotrigine) are made available in a long-acting or extended-release preparation that may (...) perampanel for refractory partial-onset seizures. Neurology . 2012 May 1. 78(18):1408-15. . Hufnagel A, Ben-Menachem E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res . 2013 Feb. 103(2-3):262-9. . Halász P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, et al. Long-term efficacy and safety

2014 eMedicine.com

179. Seizures and Epilepsy: Overview and Classification (Follow-up)

anticonvulsants (eg, lamotrigine, topiramate, valproic acid, zonisamide) have multiple mechanisms of action, and some (eg, phenytoin, carbamazepine, ethosuximide) have only 1 known mechanism of action. Anticonvulsants can be divided into large groups based on their mechanisms, as follows: Blockers of repetitive activation of the sodium channel: Phenytoin, carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, topiramate Enhancers of slow inactivation of the sodium channel: Lacosamide, rufinamide Gamma

2014 eMedicine.com

180. Frontal Lobe Epilepsy (Follow-up)

-seizure medications include gabapentin, lamotrigine, topiramate, levetiracetam, zonisamide, oxcarbazepine, pregabalin, lacosamide, clobazam, eslicarbazepine, and brivaracetam. Approximately 30% of patients with frontal lobe epilepsy will be refractory to multiple medications, and they may require evaluation for resective surgery. Other options include dietary therapy (ketogenic diet or modified Atkins diet), vagal nerve stimulation, or responsive neurostimulation. Go to for complete information

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>